Want to join the conversation?
$MRK said that with more than 200 clinical trials and more than 100 combinations in over 30 tumor types, the company is seeing the potential to drive significant growth for KEYTRUDA longer term. In 2016, $MRK will continue to prioritize resources, focusing on JANUVIA, hospital acute care, vaccines and product launches such as ZEPATIER and KEYTRUDA.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.